Jesper D. Gunst retweeted
🚨 We’re hiring! 🚨
Join the Gaebler & Ibrahim Labs for an exciting postdoc position at the intersection of virology & gene regulation! Help us uncover mechanisms behind HIV latency using cutting-edge genome engineering. More info: nature.com/naturecareers/job…
Jesper D. Gunst retweeted
Exciting news! Our survey report with
@ECDC_EU on #HIV #stigma in the #healthcare setting is now available.
Huge thanks to everyone who contributed to its success!
👉bit.ly/46kI1uN
Don't miss the presentation on Friday by @TeyNoori at #AIDS2024
Jesper D. Gunst retweeted
How to interpret and how to manage low level viremia? Hearing now from @JesperGunst with important insight from amazing session chair @Rokx1 at #YINGconf24 – at Brussels, Belgium
Jesper D. Gunst retweeted
The survey on "Measuring #HIV knowledge and attitudes in the #healthcare setting" is still available until 5 Dec!
Complete it today or spread the word in your network. 🔄
Available in 38+ languages! 🌍
Survey link: ow.ly/w7vH50QcPWv
@ECDC_EU
Jesper D. Gunst retweeted
Editorial: “Host Receptor Targeting to Treat #Covid19” by @JesperGunst and Ole Schmeltz Søgaard eviden.cc/3ScIr1C
#SARSCov2 #InfectiousDisease @AarhusUni_int @AUHdk @syctong @Josh_S_Davis @jasonroberts_pk
Jesper D. Gunst retweeted
If you work in a healthcare setting in Europe or Central Asia, you are invited to take this survey on stigma & discrimination by @ECDC_EU and @EACSociety
⏲️ Deadline: 30 November 2023
#StigmaFree
@ECDC_EU & @EACSociety are measuring HIV knowledge and attitudes in healthcare settings across Europe and Central Asia. Please help promote the survey which can be found here in 38 languages: eacsociety.org/activities/ea… Deadline is 30 November. 🙏 @EATGx @aidsactioneurop @WHO_Europe
Jesper D. Gunst retweeted
Inhibition of intracellular enzymes like TMPRSS2 that are vital for replication of #SARSCoV2 may be an effective treatment strategy for #COVID19. Gunst and Sogaard comment on recent clinical evidence for the effect of TMPRSS2 inhibitors like nafamostat. eviden.cc/3ScIr1C
Jesper D. Gunst retweeted
Exciting news! The Berlin Institute of Health at Charité @berlinnovation is launching its BIH PhD Program, focused on medical translation and innovation.
🌟 Fully funded doctoral positions for translational projects
🌟 Open for applications until Nov 22
bihealth.org/en/notices/bih-…
European AIDS Clinical Society (EACS) vil undersøge viden og holdninger om HIV blandt sundhedsfaglige på tværs af Europa.
Så hvis du har ca. 10 min til at udfylde - vil vi blive glade!
@Sygeplejeraadet @laegeforeningen @Sundpol @regionerne
eacsociety.org/activities/ea…
Jesper D. Gunst retweeted
In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod + broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1 nature.com/articles/s41591-0…
Review on Immunomodulation with IL-7 and IL-15 in #HIV-1 infection.
@viruseradicate
sciencedirect.com/science/ar…
Jesper D. Gunst retweeted
Results from the Titan Study show promise that broadly neutralising antibodies (BNABS) are a component of a future HIV Cure. hivcure.com.au/2023/09/13/bn…
Results from the TITAN trial is out.
First of all, a huge thanks to the participants and their families for investing in these trials.
Ongiong 🧵 below..
In people with HIV-1 undergoing antiretroviral treatment interruption, lefitolimod + broadly neutralizing antibodies did not delay viral rebound more than antibodies alone, raising questions of how to optimize combination immunotherapy to control HIV-1 nature.com/articles/s41591-0…
Lastly, thanks to all our collaborators.
My mentor: @ole_s_sogaard
@AUHdk @HealthAarhusUni @AarhusUni_int @NussenzweigL @AwesomeJonesLab @AlfredHealth @TheDohertyInst @DAREtoCureHIV @Oslounivsykehus @UniOslo @AalborgUH @OUHhospital @AmagerHvidovre @Rigshospitalet @RHGoedstrup
No added benefit of combining lefitolimod with bNAbs compared to bNAbs alone.
The bNAbs are doing something and support further investigation as part of curative strategies.
Additionally, we need better assays for bNAb prediction.